Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting

- Preclinical data showcase scalable AAV manufacturing, compact gene activators, and expanded Cas effector tools for precise epigenetic modulation SAN FRANCISCO--(BUSINESS WIRE)-- #ASGCT25 -- Epicrispr Biotechnologies , a biotechnology company focused on developing curative therapies, today announced five presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held May 15-17, 2025, in New Orleans, Louisiana. The presentations will highlight the company’s progress across key areas, including its lead epigenetic therapeutic candidate EPI-321, novel Cas effectors for epigenome engineering, and innovations in compact modular epigenetic activators. The accepted abstracts spotlight Epicrispr’s approach to modulating gene expression without altering the DNA sequence, enabling safer, tunable, and potentially reversible therapies. Two posters focus on the development and manufacturing of EPI-321, an rAAVrh74-delivered epigenetic therapy that will be initiating a first-in-human study for FSHD, a neuromuscular disease. Oral Presentation: Non-Human Primate (NHP) Safety Study of High-Dose EPI-321: A Novel AAV-Delivered Epigenetic Editing Gene Therapy for the Treatment of FSHD Presenter: Sid Boregowda, DVM, MS, Ph.D, DABT Session Title: Viral Vectors in Large Animal Models Date/Time: Wednesday, May 14, 2025, 3:45 – 5:30 PM CT Abstract Presentation Time: 4:45 – 5:00 PM CT Location: NOLA Theater B Poster Presentation Details: Directed Evolution and Characterization of Cas Effectors in Mammalian Cells for Expanded Epigenome Editing Space Presenter: Courtney Klappenbach, Senior Research Associate Poster Number: 617 Date/Time: Tuesday, May 13, 2025, 6:00 – 7:30 PM CT Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center Small Scale AAV Bioreactor Optimization Demonstrates Iterative Titer Gains of rAAVrh74 Serotype EPI-321, a CRISPR-mediated Epigenetic Therapy Presenter: James Kim, Associate Scientist Poster Number: 967 Date/Time: Tuesday, May 13, 2025, 6:00 – 7:30 PM CT Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center Compact DNA Demethylase-Activator Combination Modulators for CRISPR-mediated Epigenetic Gene Activation Presenter: Dan Hart, Ph.D, Head of Technology Development Poster Number: 1110 Date/Time: Wednesday, May 14, 2025, 5:30 – 7:00 PM CT Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center EPI-321 Development: Strategies to Establish a Scalable and Robust rAAVrh74 Upstream Manufacturing Process from 0.5 L to 1000 L Scale Presenter: Surabhi Godbole, Scientist I Poster Number: 1939 Date/Time: Thursday, May 15, 2025, 5:30 – 7:00 PM CT Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center About Epicrispr Biotechnologies Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company’s proprietary Gene Expression Modulation System (GEMS) enables precise, durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions. Epicrispr’s lead program, EPI-321 is in clinical trials for FSHD, and the company is advancing additional gene-modulating therapies. Epicrispr also has a research collaboration with Kite Pharma to develop next-generation CAR T-cell therapies. Learn more at www.epicrispr.com or follow us on LinkedIn . Contacts Investor Contact Benson Cheng benson.cheng@epic-bio.com Media Contact Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com